

Datasheet: MCA1085F

Description:	MOUSE ANTI HORSE MHC CLASS II MONOMORPHIC:FITC
Specificity:	MHC CLASS II MONOMORPHIC
Format:	FITC
Product Type:	Monoclonal Antibody
Clone:	CVS20
Isotype:	IgG1
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry	▪			Neat - 1/10

Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.

Target Species	Horse		
Species Cross Reactivity	Reacts with: Human, Bovine, Dog N.B. Antibody reactivity and working conditions may vary between species. Cross reactivity is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information.		
Product Form	Purified IgG conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid		
Max Ex/Em	Fluorophore	Excitation Max (nm)	Emission Max (nm)
	FITC	490	525
Preparation	Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant		
Buffer Solution	Phosphate buffered saline.		

Preservative 0.09% Sodium Azide (NaN₃)
Stabilisers 1% Bovine Serum Albumin

Approx. Protein Concentrations IgG concentration 0.1 mg/ml

Immunogen 3132 cells.

Fusion Partners Spleen cells from immunised BALB/c mice were fused with cells of the X.63-Ag8.653 mouse myeloma cell line

Specificity **Mouse anti Horse MHC Class II Monomorphic antibody, clone CVS20** recognizes monomorphic equine MHC Class II and was classified at the International Equine Leucocyte Antigen Workshop. Clone CVS20 reacts with all equine B cells and 95% of equine T cells.

The major histocompatibility complex (MHC) is a cluster of genes that are important in the immune response to infections. In horses, this is referred to as the equine leukocyte antigen (ELA) region.

Flow Cytometry Use 10ul of the suggested working dilution to label 10⁶ cells in 100ul.

- References**
1. Kydd, J.H. & Antczak, D.F. (1991) Report of the First International Workshop on Equine Leucocyte Antigens, Cambridge, UK, July 1991 [Equine Immunol. 4: 5.](#)
 2. Lunn, D.P. *et al.* (1998) Report of the Second Equine Leucocyte Antigen Workshop, Squaw valley, California, July 1995. [Vet Immunol Immunopathol. 62 \(2\): 101-43.](#)
 3. Weiss, D.J. *et al.* (2001) Regulation of expression of major histocompatibility antigens by bovine macrophages infected with *Mycobacterium avium* subsp. *paratuberculosis* or *Mycobacterium avium* subsp. *avium*. [Infect Immun. 69 \(2\): 1002-8.](#)
 4. Out, T.A. *et al.* (2002) Local T-cell activation after segmental allergen challenge in the lungs of allergic dogs. [Immunology. 105 \(4\): 499-508.](#)
 5. Carrade, D.D. *et al.* (2011) Clinicopathologic findings following intra-articular injection of autologous and allogeneic placentally derived equine mesenchymal stem cells in horses. [Cytotherapy. 13: 419-30.](#)
 6. Catchpole, B. *et al.* (2002) Generation of blood-derived dendritic cells in dogs with oral malignant melanoma. [J Comp Pathol. 126: 238-41.](#)
 7. Weiss, D.J. *et al.* (2006) Mucosal immune response in cattle with subclinical Johne's disease. [Vet Pathol. 43: 127-35.](#)
 8. Weiss, D.J. (2001) Evaluation of proliferative disorders in canine bone marrow by use of flow cytometric scatter plots and monoclonal antibodies. [Vet Pathol. 38: 512-8.](#)
 9. Sassa, Y. *et al.* (2010) Bovine macrophage degradation of scrapie and BSE PrPSc [Vet Immunol Immunopathol. 133: 33-9.](#)
 10. Carrade, D.D. *et al.* (2012) Comparative Analysis of the Immunomodulatory Properties of Equine Adult-Derived Mesenchymal Stem Cells(). [Cell Med. 4 \(1\): 1-11.](#)
 11. Hussein, H. *et al.* (2016) Cathepsin K inhibition renders equine bone marrow nucleated cells hypo-responsive to LPS and unmethylated CpG stimulation *in vitro*. [Comp Immunol Microbiol Infect Dis. 45: 40-7.](#)
 12. Maia, L. *et al.* (2016) Conditioned medium: A new alternative for cryopreservation of

- equine umbilical cord mesenchymal stem cells. [Cell Biol Int. Nov 26 \[Epub ahead of print\]](#)
13. de Moraes, C.N. *et al.* (2016) Bovine endometrial cells: a source of mesenchymal stem/progenitor cells. [Cell Biol Int. 40 \(12\): 1332-1339.](#)
14. Maumus, M. *et al.* (2016) Utility of a Mouse Model of Osteoarthritis to Demonstrate Cartilage Protection by IFN γ -Primed Equine Mesenchymal Stem Cells. [Front Immunol. 7: 392.](#)
15. Ziegler, A. *et al.* (2016) Identification and characterization of equine blood plasmacytoid dendritic cells. [Dev Comp Immunol. 65: 352-7.](#)
16. Abdelhamid, L. *et al.* (2017) Retinoic acid-mediated anti-inflammatory responses in equine immune cells stimulated by LPS and allogeneic mesenchymal stem cells. [Res Vet Sci. 114: 225-32.](#)
17. Maia, L. *et al.* (2017) A proteomic study of mesenchymal stem cells from equine umbilical cord. [Theriogenology. 100: 8-15.](#)
18. Hussein, H. *et al.* (2016) Cathepsin K inhibition renders equine bone marrow nucleated cells hypo-responsive to LPS and unmethylated CpG stimulation *in vitro*. [Comp Immunol Microbiol Infect Dis. 45: 40-7.](#)
19. Santos, V.H.D. *et al.* (2019) Evaluation of alginate hydrogel encapsulated mesenchymal stem cell migration in horses. [Res Vet Sci. 124: 38-45.](#)
20. Barberini, D.J. *et al.* (2018) Safety and tracking of intrathecal allogeneic mesenchymal stem cell transplantation in healthy and diseased horses. [Stem Cell Res Ther. 9 \(1\): 96.](#)

Further Reading 1. Burk, J. *et al.* (2013) Equine cellular therapy-from stall to bench to bedside? [Cytometry A. 83: 103-13](#)

Storage Store at +4°C or at -20°C if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use.

Guarantee 12 months from date of despatch

Health And Safety Information Material Safety Datasheet documentation #10041 available at:
10041: <https://www.bio-rad-antibodies.com/uploads/MSDS/10041.pdf>

Regulatory For research purposes only

North & South America	Tel: +1 800 265 7376 Fax: +1 919 878 3751 Email: antibody_sales_us@bio-rad.com	Worldwide	Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: antibody_sales_uk@bio-rad.com	Europe	Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: antibody_sales_de@bio-rad.com
----------------------------------	---	------------------	---	---------------	---

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://www.bio-rad-antibodies.com/datasheets)
'M364771:200529'

Printed on 22 Mar 2021